growth hormone deficiency
Recently Published Documents

Skeletal maturation can be delayed by reducing the exposure to estrogens, either by halting pubertal development through administering a GnRH analogue (GnRHa), or by blocking the conversion of androgens to estrogens through an aromatase inhibitor (AI). These agents have been investigated in children with growth disorders (off-label), either alone or in combination with recombinant human growth hormone (rhGH). GnRHa is effective in attaining a normal adult height (AH) in the treatment of children with central precocious puberty, but its effect in short children with normal timing of puberty is equivocal. If rhGH-treated children with growth hormone deficiency or those who were born small-for-gestational age are still short at pubertal onset, co-treatment with a GnRHa for 2-3 years increases AH. A similar effect was seen by adding rhGH to GnRHa treatment of children with central precocious puberty with a poor AH prediction and by adding rhGH plus GnRHa to children with congenital adrenal hyperplasia with a poor predicted adult height on conventional treatment with gluco- and mineralocorticoids. In girls with idiopathic short stature and relatively early puberty, rhGH plus GnRHa increases AH. Administration of letrozole to boys with constitutional delay of growth puberty may increase AH, and rhGH plus anastrozole may increase AH in boys with growth hormone deficiency or idiopathic short stature, but the lack of data on attained AH and potential selective loss-of-follow-up in several studies precludes firm conclusions. GnRHas appear to have a good overall safety profile, while for aromatase inhibitors conflicting data have been reported.

Синдром Прадера-Вилли - редкое наследственное заболевание, причиной которого является отсутствие отцовской копии участка хромосомы 15q11-13. Одним из проявлений данного генетического синдрома может быть соматотропная недостаточность. Именно низкорослость часто является поводом для обращения родителей пациента к врачу-эндокринологу. Для своевременной диагностики заболевания очень важен командный подход специалистов с участием генетика, эндокринолога, невропатолога с обязательным проведением генетического анализа. Обнаружение дефицита гормона роста и назначение соответствующей заместительной терапии повышает уровень медицинской и социальной адаптации ребенка. В данной статье описан случай синдрома Прадера-Вилли с соматотропной недостаточностью у 4-летней девочки, представлены преимущества и риски применения гормона роста. Prader-Willi syndrome is a rare hereditary disorder caused by the absence of a paternal copy of the 15q11-13 chromosome region. One of the manifestations of this genetic syndrome may be somatotropic insufficiency. It is the short stature that is often the reason for the patient's parents to contact an endocrinologist. For the timely diagnosis of the disease, a team approach of specialists with the participation of a geneticist, endocrinologist, neuropathologist with the obligatory genetic analysis is very important. Detection of growth hormone deficiency and the appointment of appropriate substitution therapy increases the level of medical and social adaptation of the child. This article describes a case of Prader-Willi syndrome with growth hormone deficiency in a 4-year-old girl, presents the benefits and risks of using growth hormone.

Abstract Objectives Human growth hormone (hGH) provocation test is an essential tool to assess growth hormone deficiency (GHD) in children and young adults. It is important to have a robust method to determine the hGH peak of stimulation. This work aimed to compare three common automated immunoassays for hGH quantification and to ascertain whether there are still result-related differences which can impact clinical decision. Methods We analyzed the GH provocation test for 39 young subjects from pediatric department of Montpellier hospital, admitted for suspicion of growth hormone deficiency. The full range of measurements as well as the peak level of serum GH were compared using three automated immunoassays on three different immunoanalyzers: IDS-hGH on iSYS, LIAISON-hGH on Liaison XL and Elecsys ROCHE-hGH, on COBAS 8000. Results A good correlation was obtained between methods for all measurements (r 2>0.99) by using Passing–Bablok regression analysis. Bland–Altman analysis showed the best agreement between IDS-hGH and LIAISON-hGH systems (bias=−14.5%) compared to Elecsys ROCHE-hGH (bias=28.3%). When considering stratification of the study population and a unique cutoff, there were some discrepancies in interpretation of the results especially concerning the more recent Elecsys ROCHE-hGH assay. Nevertheless, when the adequate cutoff for each method was taken into account results were well correlated for all systems. Conclusions A cutoff for Elecsys Roche-hGH method was established to better explain the results. Clinician must be aware of the use of assay-specific cutoff to correctly integrate the results of GH tests in the GHD diagnosis.